Pharmafile Logo
Pharmafocus logo
Advanced Search

IPF

Showing 15 posts of 18 posts found.

boehringer_good

Boehringer’s OFEV slows IPF disease progression by half in trials

February 26, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, IPF, ofev

Boehringer Ingelheim has revealed pooled analysis data from three trials, showing that its drug OFEV significantly reduces the risk of …

News
Gilead logo

Gilead terminates Phase II simtuzumab IPF study

January 6, 2016
Research and Development Gilead, IPF, idiopathic pulmonary fibrosis, simtuzumab

Gilead Sciences has announced the termination of its Phase II clinical study of the investigational monoclonal antibody simtuzumab in patients …

News
ofev1

Boehringer earns NICE nod for IPF drug Ofev

September 14, 2015
Sales and Marketing Boehringer Ingelheim, IPF, NICE, idiopathic pulmonary fibrosis

NICE has recommended Boehringer Ingelheim’s Ofev as a treatment for idiopathic pulmonary fibrosis after the German firm agreed to a …

News
Boehringer image

Boehringer’s beer breach at German congress

February 20, 2015
Medical Communications, Sales and Marketing ABPI, Boehringer, ERS, IPF, PMCPA, breach, code, munich

A complaint made by a pulmonologist against the competence of Boehringer Ingelheim speakers during a congress held in Germany last …

News
Ofev image

Boehringer gains EU approval for Ofev

January 19, 2015
Sales and Marketing Boehringer, Esbriet, IPF, InterMune, ingelheim, nintedanib, ofev

The European Commission has approved Boehringer Ingelheim’s Ofev as a treatment for idiopathic pulmonary fibrosis (IPF). The approval follows the …

News
Roche image

Roche buys Ariosa Diagnostics

December 2, 2014
Research and Development, Sales and Marketing IPF, IQuum, InterMune, Roche, ariosa, cfdna, diabetes, genia, seragon

Roche has purchased the privately-held US company Ariosa Diagnostics for an undisclosed fee as it looks to expand further into …

News
BI image

Boehringer’s lung cancer drug Vargatef sees EU approval

November 28, 2014
Sales and Marketing Boehringer, EU, Europe, IPF, NSCLC, lung cancer, nintedanib, ofev, vargatef

Boehringer Ingelheim’s nintedanib has received its second nod in Europe this month with the European Commission approving it for the …

News

Growing IPF drugs market evident at ERS Congress

November 3, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ERS, Esbriet, IPF, elf, european respiratory society, ofev

Arriving in Germany for this year’s European Respiratory Society (ERS) International Congress 2014, what awaited Pharmafile at the Ausgang was …

Feature
Boehringer image

Boehringer seeks more indications for IPF drug

October 22, 2014
Research and Development, Sales and Marketing Boehringer, IPF, NSCLC, colectoral, crc, nintedanib, ofev

Boehringer Ingelheim’s nintedanib has entered Phase III studies for the treatment of colorectal cancer (CRC), which could add to the …

News
Boehringer image

Boehringer and Roche IPF drugs win FDA approval

October 16, 2014
Research and Development, Sales and Marketing Boehringer, ERS, Esbriet, FDA, IPF, InterMune, Roche, US, lung scarring, lungs, ofev

The FDA has approved both Roche’s Esbriet (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib) for the treatment of the fatal lung …

News

Boehringer’s lung cancer drug gets EMA nod

September 29, 2014
Sales and Marketing Boehringer, IPF, docetaxel, ingelheim, lung cancer, nintedanib

The EMA has issued a positive opinion for the approval of Boehringer Ingelheim’s nintedanib in combination with docetaxel for the …

News
ERS event image

InterMune’s IPF drug shines at ERS Congress

September 10, 2014
Research and Development, Sales and Marketing Boehringer, ERS, Esbriet, IPF, InterMune, idiopathic pulmonary fibrosis, munich, pirfenidone

InterMune has posted positive data for its lung-scarring drug at this year’s European Respiratory Society Annual Congress 2014 (ERS). Pharmafile …

News
roche_glass_building

Roche pays $8.3bn for InterMune

August 26, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Genentech, IPF, Illumina, InterMune, Roche

Roche has stumped up $8.3 billion in cash to pay for US biotech firm InterMune and will gain access to …

News
InterMune image

InterMune stock jumps on suitor claims

August 14, 2014
Sales and Marketing Boehringer, Esbriet, FDA, GSK, IPF, InterMune

Riding high of the success of its new lung drug Esbriet, InterMune has become the focus of some serious takeover …

News

IPF grabs headlines at American Thoracic Society conference

July 21, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing IPF, ats, ats 2014, brett wells, idiopathic pulmonary fibrosis, san diego, thoracic society

Just prior to landing in San Diego it was somewhat disconcerting to see fire spreading across the terrain and huge …

Feature

Latest content

FDA grants marketing authorisation to DNA test for predisposition to certain cancers

October 2, 2023

Biogen’s biosimilar Tofidence approved by FDA

October 2, 2023

Austrian state secretary to speak at FlyPharma Europe 2023

September 29, 2023

Karuna Therapeutics submits NDA to FDA for schizophrenia treatment

September 29, 2023

Kura Oncology shares preclinical data for NSCLC treatment

September 29, 2023